Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity.
Liu F, Zhou Q, Jiang HF, Zhang TT, Miao C, Xu XH, Wu JX, Yin SL, Xu SJ, Peng JY, Gao PP, Cao X, Pan F, He X, Chen XQ. Liu F, et al. Among authors: peng jy. J Exp Clin Cancer Res. 2023 May 10;42(1):118. doi: 10.1186/s13046-023-02686-1. J Exp Clin Cancer Res. 2023. PMID: 37161450 Free PMC article.
Zebrafish model of hyperuricemia.
Deng Q, Wang XQ, Meng FY, Peng ZN, Yan WT, Liu N, Peng JY. Deng Q, et al. Among authors: peng jy. Int J Rheum Dis. 2024 May;27(5):e15160. doi: 10.1111/1756-185X.15160. Int J Rheum Dis. 2024. PMID: 38685792 No abstract available.
Nomogram-based risk assessment model for left ventricular hypertrophy in patients with essential hypertension: Incorporating clinical characteristics and biomarkers.
Wang CC, Liang LK, Luo SM, Wang HC, Wang XL, Cheng YH, Pan GM, Peng JY, Han SJ, Wang X. Wang CC, et al. Among authors: peng jy. J Clin Hypertens (Greenwich). 2024 Apr;26(4):363-373. doi: 10.1111/jch.14786. Epub 2024 Mar 2. J Clin Hypertens (Greenwich). 2024. PMID: 38430459 Free PMC article.
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
Chen GL, Liu Y, Gao XF, Wu KQ, Yang YK, Chen Y, Peng CG, Jin TH, Huang YB, Zhang YW, Su J, Jiang Q, Guo T, Zhao J, Peng XN, Peng JY, Li SX, Sun YL, Zhang HM, Fu YL, Luo D, Ma Y, Shen ZW, Zhang YT, Shou ZF. Chen GL, et al. Among authors: peng jy. Diabetes Obes Metab. 2024 Apr;26(4):1395-1406. doi: 10.1111/dom.15441. Epub 2024 Jan 29. Diabetes Obes Metab. 2024. PMID: 38287130 Clinical Trial.
216 results